Antiproliferative and apoptotic activities of tosylcyclonovobiocic acids as potent heat shock protein 90 inhibitors in human cancer cells
Introduction
Heat shock protein 90 (hsp90) is a ubiquitous molecular chaperone essential for the folding, maturation, stability and function of a wide range of client proteins [1]. Many of its substrates, namely protein kinases (HER2, Akt, raf-1, cdk4) and transcription factors (steroid hormone receptors, p53, HIF-1α) are involved in cell signalling, growth and/or survival, angiogenesis, metastasis and implicated in the pathogenesis of human cancers [2], [3]. Since inhibitors exert broad-spectrum antitumour activity as they impact multiple oncogenic pathways at the same time, hsp90 has emerged as an attractive therapeutic target in diverse cancers in which signal transduction pathways are persistently activated [4], [5]. In vitro and in vivo, the chaperone activity of hsp90 depends on ATP binding and hydrolysis [6], [7]. Natural product antibiotics of the ansamycins geldanamycin (GA), and its less toxic derivatives, 17-allylamino-17-demethoxygeldanamycin (17-AAG) and 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (17-DMAG) or the macrolide radicicol classes bind the N-terminal ATP-binding pocket of hsp90 and impair its chaperone function, resulting in depletion of many client proteins [8], [9]. Although less hepatotoxic than GA, 17-AAG is poorly soluble, difficult to formulate and undergoes extensive metabolism leading to non-target-based effects [10]. Radicicol binds to hsp90 with much higher affinity than GA and 17-AAG and is more potent at inhibiting hsp90 ATPase activity in vitro [11] but it lacks antitumour activity in animals because of its rapid metabolic inactivation. Besides these natural compounds, purine-based inhibitors of hsp90 have been developed by rational design [12].
In addition to the identification of the N-terminal ATP-binding site, the specific binding of the coumarin antibiotic novobiocin to a previously unrecognized ATP-binding domain in the C-terminal region of hsp90 has been reported [13]. Novobiocin disrupts both C- and N-terminal nucleotide binding and antagonizes the binding of GA or radicicol to hsp90 [14]. Therefore the C-terminal half of the hsp90 represents a second important approach for the development of selective inhibitors. At high concentration, novobiocin is able to interfere with the chaperone function of hsp90 and to deplete tumour cells of a series of hsp90-dependent signalling proteins [15]. Among more active analogues of novobiocin, Blagg et al. highlighted the crucial role of the noviose moiety at the 7-position of the coumarin ring for the biological activity whereas the 4-hydroxy and 8-methyl groups are not indispensable [16]. In more recent studies, 3′-descarbamoyl-4-deshydroxynovobiocin proved to be a more effective and selective hsp90 inhibitor [17]. As part of our research devoted to nonsugar coumarin analogues that target hsp90, we recently showed that removal of the noviose moiety together with introduction of a tosyl substituent at C-4 or C-7 coumarins provided 4- or 7-tosylcyclonovobiocic acid (4TCNA or 7TCNA) as lead compounds [18]. Biological evaluation of these derivatives in MCF-7 breast cancer cells revealed higher potency to induce the proteasome-mediated degradation of several known hsp90 client proteins and stronger antiproliferative activity as compared to the parent compound novobiocin. In addition, 4TCNA was a potent inducer of programmed cell death. In view of these findings, the purpose of this study was to examine the potential of novobiocin, 4TCNA and 7TCNA to affect the fate of a subset of hsp90 client proteins and to inhibit proliferation or induce apoptosis in a panel of cancer cells.
Section snippets
Cell culture and reagents
Human breast cancer MCF-7, T47D and MDA-MB231, colon cancer Caco2 and HT29, endometrial carcinoma Ishikawa and ovary IGROV1 cells were grown in Dulbecco’s modified eagle medium (DMEM) supplemented with 10% FCS, 2 mM l-glutamine, 50 U/ml penicillin and 50 μg/ml streptomycin in a humidified atmosphere at 37 °C under 5% CO2. Stock solutions of novobiocin and derivatives were prepared in DMSO. In all studies, an equivalent amount of DMSO vehicle was added as control. Primary antibodies used were: raf-1
Effects of novobiocin, 4TCNA and 7TCNA on viability in cancer cells
The antiproliferative effects of novobiocin, 4TCNA and 7TCNA corresponding to 6e and 6f, respectively [18] (Fig. 1) were evaluated by MTT in various human cancer cell lines (Table 1). All cell lines demonstrated a decrease in cell viability following exposure for 72 h to increasing concentrations of 4TCNA with IC50 ranging from 37 to 62 μM. The T47D breast cancer cell line was significantly more sensitive (P < 0.01) and Caco2 colon cancer cells were less responsive (P < 0.001) to growth inhibition by
Discussion
The aim of this study was to investigate the potential of new novobiocin derivatives to affect the fate of a subset of signalling oncoproteins that are dependent on the hsp90 chaperone for their maturation and function. Highly selective and safe hsp90 inhibitors targeting tumour specific client proteins may provide clinical benefits in the treatment of diseases like cancer. For instance overexpression of HER2 in 30–40% of breast, ovarian, prostate and non-small cell lung cancers is linked to
Conflict of interest statement
None declared.
Acknowledgements
We thank C. Farago for assistance in statistical analysis. This work was supported by the Ligue Nationale contre le Cancer (Comités du Cher, de l’Indre et des Hauts de Seine to J.-M. R. and Comité de Paris, grant no. R04/7572 to M.-G.C.). G. Le Bras had a fellowship from Servier.
References (34)
Hsp90 inhibitors as novel cancer chemotherapeutic agents
Trends Mol. Med.
(2002)- et al.
The importance of ATP binding and hydrolysis by Hsp90 in formation and function of protein heterocomplexes
J. Biol. Chem.
(1999) - et al.
The heat shock protein 90 antagonist novobiocin interacts with a previously unrecognized ATP-binding domain in the carboxyl terminus of the chaperone
J. Biol. Chem.
(2000) - et al.
A nucleotide-dependent molecular switch controls ATP binding at the C-terminal domain of Hsp90: N-terminal nucleotide binding unmasks a C-terminal binding pocket
J. Biol. Chem.
(2002) - et al.
Regulation of p21WAF1/CIP1 stability by WISp39, a Hsp90 binding TPR protein
Mol. Cell
(2005) - et al.
Protein complexes activate distinct caspase cascades in death receptor and stress-induced apoptosis
Exp. Cell Res.
(2000) Apoptosis and tumourigenesis
Curr. Opin. Genet. Dev.
(2002)Endometrial cancer
Obst. Gyn. Reprod. Med.
(2007)- et al.
Systemic therapy for advanced hepatocellular carcinoma: a review
Eur. J. Cancer
(2004) - et al.
The hallmarks of cancer
Cell
(2000)
Synthesis and biological activity of simplified denoviose-coumarins related to novobiocin as potent inhibitors of heat-shock protein 90 (hsp90)
Bioorg. Med. Chem. Lett.
Regulation of signaling protein function and trafficking by the hsp90/hsp70-based chaperone machinery
Exp. Biol. Med.
Hsp90: chaperoning signal transduction
J. Cell. Physiol.
HSP90 as a new therapeutic target for cancer therapy: the story unfolds
Expert Opin. Biol. Ther.
Targeting multiple signal transduction pathways through inhibition of Hsp90
J. Mol. Med.
ATP binding and hydrolysis are essential to the function of the Hsp90 molecular chaperone in vivo
EMBO J.
Depletion of p185erbB2, Raf-1 and mutant p53 proteins by geldanamycin derivatives correlates with antiproliferative activity
Cancer Chemother. Pharmacol.
Cited by (55)
Praseodymium(III)-Catalyzed Regioselective Synthesis of C<inf>3</inf>-N-Substituted Coumarins with Coumarins and Azides
2017, Journal of Organic ChemistryFerrocenyl and organic novobiocin derivatives: Synthesis and their in vitro biological activity
2017, Journal of Inorganic BiochemistryCitation Excerpt :A typical example of coumarin containing compounds is novobiocin (1, Fig. 1), a naturally occurring coumarin antibiotic isolated from Streptomyces strains. Novobiocin (1) has attracted great attention due to its broad spectrum of biological properties including antimicrobial, anticancer and antimalarial activities [16–18]. It has been found to act by inhibiting pathologically important enzymes such as DNA gyrase [19,20], heat shock protein 90 (Hsp90) and related client proteins [7,21] through the blockade of their ATPase activity.
Novel 1,6-naphthyridin-2(1H)-ones as potential anticancer agents targeting Hsp90
2016, European Journal of Medicinal ChemistryCitation Excerpt :Since to date, no cocrystal structure of Hsp90 bound to C-terminal inhibitors has been yet reported. Preliminary investigations on novobiocin analogs revealed structural key elements for elucidation of the Hsp90 C-terminal binding pocket and subsequent structure–activity relationships led to identify promising synthetic compounds that exhibit potent antiproliferative activity against a large panel of cancer cell lines [9–23]. The synthesis of these libraries has helped to highlight the following structure–activity relationships (SARs): (1) the lactone present in the coumarin core is not essential for Hsp90 inhibition while 4-hydroxy lowers the activity; (2) replacement of the noviose at the 7-position with hydrophilic amines residues is tolerated without compromising inhibitory activity (3) the aromatic side chain and the amide linker are critical for antiproliferative activity (Fig. 1).
Palladium-Catalyzed Coupling of N-Aminoazoles with 3-Halo-Substituted Quinolin-2(1H)-ones, Coumarins, Quinoxalin-2(1H)-ones, and Chromenes
2015, European Journal of Organic ChemistrySynthesis and antiproliferative activity of novobiocin analogues as potential hsp90 inhibitors Dedicated to the memory of Dr. Christine Radanyi.
2014, European Journal of Medicinal ChemistryEstrogen receptor signaling as a target for novel breast cancer therapeutics
2013, Biochemical Pharmacology